Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (49,044,477)	$ (20,520,131)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash consideration for acquired in-process research and development		6,541,485
Changes in fair value of contingent consideration liability	16,265,010
Impairment charge	0	1,000,000
Stock-based compensation expense	2,576,006	1,264,231
Depreciation and amortization	298,057	387,321
Unrealized gain on foreign currency exchange	(19,073)	(5,761)
Changes in fair value of warrant liability		(30,000)
Changes in operating assets and liabilities:
Accounts receivable	(3,589,024)	2,440,759
Prepaid expenses and other current assets	(1,371,312)	133,001
Accounts payable	594,060	(354,628)
Accrued expenses and other liabilities	6,987,815	(779,651)
Tax refund receivable	(7,133,698)	379,877
Deferred taxes		(58,500)
Net cash used in operating activities	(34,436,636)	(9,601,997)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sales and maturities of short-term investments	56,406,564
Purchases of short-term investments	(128,159,098)	(28,257,379)
Purchases of property and equipment	(203,957)	(1,227)
Cash paid for internally developed patents	(138,464)	(27,772)
Net cash used in investing activities	(72,094,955)	(28,286,378)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash paid in conjunction with warrant exchange		(25,000)
Proceeds from exercises of warrants	41,038,458	30,324
Proceeds from issuance of common stock in at-the-market offering, net	48,156,072
Proceeds from issuance of common stock and pre-funded warrants in public offering, net	124,027,815
Proceeds from issuance of common stock in registered direct offering, net		12,668,784
Proceeds from issuance of notes payable	632,000
Payments of notes payable	(632,000)	(292,002)
Proceeds from conditional economic incentive		150,000
Proceeds from issuance of common stock from Employee Stock Purchase Plan	135,471
Proceeds from exercises of stock options	128,896
Net cash provided by financing activities	213,486,712	12,532,106
Net increase (decrease) in cash, cash equivalents and restricted cash	106,955,121	(25,356,269)
Cash, cash equivalents and restricted cash — beginning of year	8,996,860	34,353,129
Cash, cash equivalents and restricted cash — end of year	115,951,981	8,996,860
SUPPLEMENTAL NON-CASH ACTIVITIES:
Common stock issued related to contingent consideration liability	13,625,010
Common stock issued for acquired in-process research and development		3,791,485
Operating lease liability and right of use asset addition	$ 338,212	$ 1,744,128